US20040122000A1
(en)
*
|
1981-01-07 |
2004-06-24 |
Vertex Pharmaceuticals Incorporated. |
Inhibitors of aspartyl protease
|
UA59384C2
(uk)
*
|
1996-12-20 |
2003-09-15 |
Пфайзер, Інк. |
Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
|
US6436989B1
(en)
*
|
1997-12-24 |
2002-08-20 |
Vertex Pharmaceuticals, Incorporated |
Prodrugs of aspartyl protease inhibitors
|
US6686366B1
(en)
|
1998-06-02 |
2004-02-03 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6878716B1
(en)
|
1998-06-02 |
2005-04-12 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptor and uses thereof
|
BR9911612A
(pt)
|
1998-06-02 |
2001-02-06 |
Osi Pharm Inc |
Composições de pirrolo[2,3d]pirimidina e seus usos
|
GB9815567D0
(en)
*
|
1998-07-18 |
1998-09-16 |
Glaxo Group Ltd |
Antiviral compound
|
WO2000018384A2
(en)
*
|
1998-09-28 |
2000-04-06 |
Glaxo Group Limited |
Antiviral combinations comprising (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic acid isopropyl ester and amprenavir
|
GB9914821D0
(en)
*
|
1999-06-24 |
1999-08-25 |
Glaxo Group Ltd |
Compounds
|
US6664252B2
(en)
|
1999-12-02 |
2003-12-16 |
Osi Pharmaceuticals, Inc. |
4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
|
US6680322B2
(en)
|
1999-12-02 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US7160890B2
(en)
|
1999-12-02 |
2007-01-09 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6680324B2
(en)
|
2000-12-01 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US6673802B2
(en)
|
2000-12-01 |
2004-01-06 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
HU229224B1
(en)
|
2001-02-14 |
2013-09-30 |
Tibotec Pharmaceuticals Ltd Little Island |
2-(substituted-amino)-benzothiazole sulfonamide compounds having broadspectrum hiv protease inhibitor activity and medicaments containing them
|
EA007383B1
(ru)
|
2001-04-09 |
2006-10-27 |
Тиботек Фармасьютикалз Лтд. |
2-(замещенный амино)бензоксазолсульфонамидные ингибиторы вич-протеазы широкого спектра
|
DK1387842T3
(da)
|
2001-05-11 |
2009-08-10 |
Tibotec Pharm Ltd |
Bredspektrede 2-amino-benzoxazolsulfonamid-HIV-protease-inhibitorer
|
US7576084B2
(en)
*
|
2001-10-12 |
2009-08-18 |
Choongwae Pharma Corporation |
Reverse-turn mimetics and method relating thereto
|
WO2003048120A2
(en)
|
2001-11-30 |
2003-06-12 |
Osi Pharmaceuticals, Inc. |
2-aryl pyrrologpyrimidines for a1 and a3 receptors
|
TWI286476B
(en)
*
|
2001-12-12 |
2007-09-11 |
Tibotec Pharm Ltd |
Combination of cytochrome P450 dependent protease inhibitors
|
US20030229067A1
(en)
|
2001-12-20 |
2003-12-11 |
Arlindo Castelhano |
Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
|
WO2003053366A2
(en)
|
2001-12-20 |
2003-07-03 |
Osi Pharmaceuticals, Inc. |
Pyrimidine a2b selective antagonist compounds, their synthesis and use
|
JP4578101B2
(ja)
|
2001-12-21 |
2010-11-10 |
テイボテク・フアーマシユーチカルズ・リミテツド |
幅広いスペクトルのhivプロテアーゼ阻害剤である複素環置換フェニル含有スルホンアミド
|
MY142238A
(en)
|
2002-03-12 |
2010-11-15 |
Tibotec Pharm Ltd |
Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
|
US7157489B2
(en)
*
|
2002-03-12 |
2007-01-02 |
The Board Of Trustees Of The University Of Illinois |
HIV protease inhibitors
|
WO2003091264A2
(en)
|
2002-04-26 |
2003-11-06 |
Gilead Sciences, Inc. |
Non nucleoside reverse transcriptase inhibitors
|
US7462636B2
(en)
|
2002-05-17 |
2008-12-09 |
Tibotec Pharmaceuticals Ltd |
Broadspectrum substituted benzisoxazole sulfonamide HIV protease inhibitors
|
PL375307A1
(en)
|
2002-08-14 |
2005-11-28 |
Tibotec Pharmaceuticals Ltd. |
Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
CA2425031A1
(en)
*
|
2003-04-01 |
2004-10-01 |
Smithkline Beecham Corporation |
Pharmaceutical compositions
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
WO2004096285A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Anti-infective phosphonate conjugates
|
WO2004096287A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
EA200501676A1
(ru)
|
2003-04-25 |
2006-04-28 |
Джилид Сайэнс, Инк. |
Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты)
|
US7432261B2
(en)
|
2003-04-25 |
2008-10-07 |
Gilead Sciences, Inc. |
Anti-inflammatory phosphonate compounds
|
ATE490788T1
(de)
|
2003-04-25 |
2010-12-15 |
Gilead Sciences Inc |
Antivirale phosphonate analoge
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
JP4738333B2
(ja)
*
|
2003-07-09 |
2011-08-03 |
パラテック ファーマシューティカルズ インコーポレイテッド |
9−アミノメチルテトラサイクリン化合物のプロドラッグ
|
WO2005009943A2
(en)
|
2003-07-09 |
2005-02-03 |
Paratek Pharmaceuticals, Inc. |
Substituted tetracycline compounds
|
US20050119163A1
(en)
*
|
2003-09-18 |
2005-06-02 |
The Government Of The United States Of America, As Represented By The Secretary, |
SH2 domain binding inhibitors
|
WO2005044279A1
(en)
|
2003-10-24 |
2005-05-19 |
Gilead Sciences, Inc. |
Purine nucleoside phosphonate conjugates
|
WO2005044308A1
(en)
|
2003-10-24 |
2005-05-19 |
Gilead Sciences, Inc. |
Phosphonate analogs of antimetabolites
|
US8193227B2
(en)
|
2003-12-11 |
2012-06-05 |
Abbott Laboratories |
HIV protease inhibiting compounds
|
US20050131042A1
(en)
*
|
2003-12-11 |
2005-06-16 |
Flentge Charles A. |
HIV protease inhibiting compounds
|
US7834043B2
(en)
*
|
2003-12-11 |
2010-11-16 |
Abbott Laboratories |
HIV protease inhibiting compounds
|
PL1699455T3
(pl)
*
|
2003-12-15 |
2013-10-31 |
Merck Sharp & Dohme |
Heterocykliczne inhibitory proteaz aspartylowych
|
EP1697384B1
(en)
|
2003-12-18 |
2008-04-02 |
Janssen Pharmaceutica N.V. |
Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
|
JP2007515495A
(ja)
|
2003-12-22 |
2007-06-14 |
ギリアード サイエンシーズ, インコーポレイテッド |
4’−置換カルボビル誘導体およびアバカビル誘導体ならびにhivおよびhcv抗ウイルス活性を有する関連化合物
|
WO2006014282A2
(en)
|
2004-07-06 |
2006-02-09 |
Abbott Laboratories |
Prodrugs of hiv protease inhibitors
|
EP1778251B1
(en)
|
2004-07-27 |
2011-04-13 |
Gilead Sciences, Inc. |
Nucleoside phosphonate conjugates as anti hiv agents
|
CN1942436B
(zh)
*
|
2004-08-02 |
2011-03-23 |
阿姆布里利亚生物制药公司 |
基于赖氨酸的化合物
|
US7388008B2
(en)
*
|
2004-08-02 |
2008-06-17 |
Ambrilia Biopharma Inc. |
Lysine based compounds
|
WO2006024492A2
(en)
|
2004-08-30 |
2006-03-09 |
Interstitial Therapeutics |
Medical implant provided with inhibitors of atp synthesis
|
JP2008521862A
(ja)
|
2004-12-01 |
2008-06-26 |
デブジェン エヌブイ |
イオンチャンネル、特にkvファミリーのイオンチャンネルと相互作用する5−カルボキサミド置換チアゾール誘導体
|
NI200700147A
(es)
|
2004-12-08 |
2019-05-10 |
Janssen Pharmaceutica Nv |
Derivados de quinazolina inhibidores de cinasas dirigidos a multip
|
EP1835807A1
(en)
|
2004-12-17 |
2007-09-26 |
Devgen N.V. |
Nematicidal compositions
|
DE602006010979D1
(de)
*
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
EP1855672A4
(en)
*
|
2005-03-11 |
2011-11-30 |
Glaxosmithkline Llc |
HIV PROTEASE INHIBITORS
|
AR053845A1
(es)
|
2005-04-15 |
2007-05-23 |
Tibotec Pharm Ltd |
5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
|
US20060287316A1
(en)
*
|
2005-04-27 |
2006-12-21 |
Ambrilia Biopharma Inc. |
Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
|
WO2007045496A1
(en)
|
2005-10-21 |
2007-04-26 |
Universiteit Antwerpen |
Novel urokinase inhibitors
|
AR057182A1
(es)
|
2005-11-28 |
2007-11-21 |
Tibotec Pharm Ltd |
Compuestos de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
|
TWI432438B
(zh)
|
2005-11-28 |
2014-04-01 |
Tibotec Pharm Ltd |
作為hiv蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物及衍生物
|
ES2452718T3
(es)
*
|
2005-11-30 |
2014-04-02 |
Taimed Biologics, Inc. |
Profármacos a base de lisina de inhibidores de la aspartil proteasa y procesos para su preparación
|
CN117903302A
(zh)
|
2005-11-30 |
2024-04-19 |
Abbvie 公司 |
抗-Aβ球聚体抗体,其相关产品,生产所述抗体的方法,所述抗体的应用以及使用方法
|
PL1976877T5
(pl)
|
2005-11-30 |
2017-09-29 |
Abbvie Inc |
Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
|
CN101346390B
(zh)
*
|
2005-12-27 |
2011-11-09 |
大塚制药株式会社 |
水溶性苯并氮杂*化合物及其药物组合物
|
WO2008006884A2
(en)
|
2006-07-13 |
2008-01-17 |
Janssen Pharmaceutica N.V. |
Mtki quinazoline derivatives
|
EP2063918B1
(en)
|
2006-09-08 |
2014-02-26 |
Piramal Imaging SA |
Compounds and methods for 18f labeled agents
|
JP5401652B2
(ja)
|
2006-09-21 |
2014-01-29 |
タイメッド バイオロジクス インコーポレイテッド |
プロテアーゼ阻害剤
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP2486928A1
(en)
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
MX2009009850A
(es)
|
2007-03-12 |
2009-09-24 |
Nektar Therapeutics |
Conjugados de inhibidor de oligomero-proteasa.
|
EP2185562B1
(en)
|
2007-07-27 |
2015-12-02 |
Janssen Pharmaceutica, N.V. |
Pyrrolopyrimidines useful for the treatment of proliferative diseases
|
EP2053033A1
(en)
|
2007-10-26 |
2009-04-29 |
Bayer Schering Pharma AG |
Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
|
EP2100900A1
(en)
|
2008-03-07 |
2009-09-16 |
Universitätsspital Basel |
Bombesin analog peptide antagonist conjugates
|
CA2716079C
(en)
|
2008-03-10 |
2018-01-16 |
Janssen Pharmaceutica Nv |
4-aryl-2-anilino-pyrimidines as plk kinase inhibitors
|
EP2262538B1
(en)
*
|
2008-03-12 |
2014-12-10 |
Nektar Therapeutics |
Oligomer-amino acid conjugate
|
EP2116236A1
(en)
|
2008-04-21 |
2009-11-11 |
Université de Mons-Hainaut |
Bisbenzamidine derivatives for use as antioxidant
|
AU2009268681B2
(en)
|
2008-07-08 |
2014-10-02 |
Gilead Sciences, Inc. |
Salts of HIV inhibitor compounds
|
ES2623794T3
(es)
|
2008-12-09 |
2017-07-12 |
Gilead Sciences, Inc. |
Intermedios para la preparación de moduladores de receptores tipo toll
|
US20120135965A1
(en)
*
|
2009-05-20 |
2012-05-31 |
Ranbaxy Laboratories Limited |
Amorphous fosamprenavir calcium
|
EP2440249A2
(en)
|
2009-06-12 |
2012-04-18 |
Nektar Therapeutics |
Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
|
WO2011033469A1
(en)
|
2009-09-16 |
2011-03-24 |
Ranbaxy Laboratories Limited |
Process for the preparation of fosamprenavir calcium
|
WO2011061590A1
(en)
|
2009-11-17 |
2011-05-26 |
Hetero Research Foundation |
Novel carboxamide derivatives as hiv inhibitors
|
EP2501431B1
(en)
|
2009-11-19 |
2020-01-08 |
Wellinq Medical B.V. |
Narrow profile composition-releasing expandable medical balloon catheter
|
US20110165202A1
(en)
*
|
2010-01-07 |
2011-07-07 |
Pliva Hrvatska D.O.O. |
Solid state forms of fosamprenavir calcium salt and processes for preparation thereof
|
DK3494972T3
(da)
|
2010-01-27 |
2024-01-29 |
Viiv Healthcare Co |
Kombinationer af dolutegravir og lamivudin til behandling af HIV-infektion
|
US20110223131A1
(en)
|
2010-02-24 |
2011-09-15 |
Gilead Sciences, Inc. |
Antiviral compounds
|
US20110224443A1
(en)
*
|
2010-03-15 |
2011-09-15 |
Venkata Naga Brahmeshwara Rao Mandava |
Preparation of fosamprenavir calcium
|
WO2011114212A1
(en)
|
2010-03-19 |
2011-09-22 |
Lupin Limited |
Ammonium, calcium and tris salts of fosamprenavir
|
CA2796339C
(en)
|
2010-04-15 |
2020-03-31 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
WO2011141515A1
(en)
|
2010-05-14 |
2011-11-17 |
Bayer Pharma Aktiengesellschaft |
Diagnostic agents for amyloid beta imaging
|
WO2011158259A1
(en)
|
2010-06-18 |
2011-12-22 |
Matrix Laboratories Ltd |
Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts thereof
|
US8785648B1
(en)
|
2010-08-10 |
2014-07-22 |
The Regents Of The University Of California |
PKC-epsilon inhibitors
|
CA2808187A1
(en)
|
2010-08-14 |
2012-02-23 |
Abbvie Inc. |
Amyloid-beta binding proteins
|
WO2012032389A2
(en)
|
2010-09-10 |
2012-03-15 |
Lupin Limited |
Process for preparation of substantially pure fosamprenavir calcium and its intermediates
|
GB201019043D0
(en)
|
2010-11-10 |
2010-12-22 |
Protea Biopharma N V |
Use of 2',5'-oligoadenylate derivative compounds
|
WO2012085625A1
(en)
|
2010-12-21 |
2012-06-28 |
Lupin Limited |
Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
|
US8993786B2
(en)
*
|
2011-02-10 |
2015-03-31 |
Mylan Laboratories Ltd. |
Crystalline fosamprenavir calcium and process for the preparation thereof
|
RU2711799C2
(ru)
|
2011-06-21 |
2020-01-22 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ иРНК ДЛЯ СХОДНОГО С АНГИОПОЭТИНОМ 3(ANGPTL3) БЕЛКА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
EP2723390B1
(en)
|
2011-06-23 |
2017-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
WO2013009844A2
(en)
*
|
2011-07-11 |
2013-01-17 |
Purdue Research Foundation |
C-3 substituted bicyclooctane based hiv protease inhibitors
|
WO2013011485A1
(en)
|
2011-07-20 |
2013-01-24 |
Ranbaxy Laboratories Limited |
Process for the preparation of sulfonamides useful as retroviral protease inhibitors
|
WO2013105118A1
(en)
|
2012-01-10 |
2013-07-18 |
Council Of Scientific & Industrial Research |
A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
EP2700396A3
(en)
|
2012-06-20 |
2015-04-29 |
Sylphar Nv |
Strip for the delivery of oral care compositions
|
WO2014059034A2
(en)
|
2012-10-09 |
2014-04-17 |
President And Fellows Of Harvard College |
Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
|
AU2013340559B2
(en)
|
2012-10-29 |
2018-03-15 |
Cipla Limited |
Antiviral phosphonate analogues and process for preparation thereof
|
HUE035887T2
(en)
|
2012-12-05 |
2018-05-28 |
Alnylam Pharmaceuticals Inc |
PCSK9 iRNA preparations and methods for their use
|
MX366660B
(es)
|
2013-03-14 |
2019-07-18 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
|
UY35582A
(es)
|
2013-05-22 |
2014-10-31 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
|
KR102234623B1
(ko)
|
2013-05-22 |
2021-04-02 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 조성물 및 이의 사용 방법
|
CA3107872A1
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
EP3105331B1
(en)
|
2014-02-11 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
SG11201609376SA
(en)
|
2014-05-22 |
2016-12-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
EP3180003B1
(en)
|
2014-07-01 |
2022-01-12 |
The Regents of the University of California |
Pkc-epsilon inhibitors
|
WO2016001907A1
(en)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
|
PL3166607T3
(pl)
|
2014-07-11 |
2023-02-20 |
Gilead Sciences, Inc. |
Modulatory receptorów toll-podobnych do leczenia hiv
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
WO2016069955A1
(en)
|
2014-10-29 |
2016-05-06 |
Wisconsin Alumni Research Foundation |
Boronic acid inhibitors of hiv protease
|
EP3212794B1
(en)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
JP2017535552A
(ja)
|
2014-11-17 |
2017-11-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法
|
WO2016083490A1
(en)
|
2014-11-27 |
2016-06-02 |
Remynd Nv |
Compounds for the treatment of amyloid-associated diseases
|
JP2018510621A
(ja)
|
2015-02-13 |
2018-04-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
パタチン様ホスホリパーゼドメイン含有3(PNPLA3)iRNA組成物およびその使用方法
|
TWI723986B
(zh)
|
2015-04-13 |
2021-04-11 |
美商阿尼拉製藥公司 |
類血管生成素3(ANGPTL3)iRNA組成物及其用途方法
|
PT3288637T
(pt)
|
2015-04-28 |
2022-10-11 |
Newsouth Innovations Pty Ltd |
Visar nad+ para tratar comprometimento cognitivo, neuropatias e inatividade induzidos por quimioterapia e radioterapia
|
CN108271386B
(zh)
|
2015-05-06 |
2022-07-15 |
阿尔尼拉姆医药品有限公司 |
因子XII(哈格曼因子)(F12)、激肽释放酶B、血浆(夫列契因子)1(KLKB1)和激肽原1(KNG1)iRNA组合物及其使用方法
|
EP3310918B1
(en)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
MA42818A
(fr)
|
2015-09-15 |
2018-07-25 |
Gilead Sciences Inc |
Modulateurs de récepteurs de type toll pour le traitement du vih
|
US11091759B2
(en)
|
2015-12-07 |
2021-08-17 |
Genzyme Corporation |
Methods and compositions for treating a Serpinc1-associated disorder
|
WO2017100542A1
(en)
|
2015-12-10 |
2017-06-15 |
Alnylam Pharmaceuticals, Inc. |
Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
|
EP3469083A1
(en)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
KR20230166146A
(ko)
|
2016-12-16 |
2023-12-06 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
|
EP3621963B1
(en)
|
2017-05-11 |
2024-01-24 |
Remynd N.V. |
Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders
|
JP7384783B2
(ja)
|
2017-07-21 |
2023-11-21 |
ヴィーブ ヘルスケア カンパニー |
Hiv感染症及びaidsを治療するためのレジメン
|
EP3960740B1
(en)
|
2017-08-01 |
2023-11-15 |
Gilead Sciences, Inc. |
Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections
|
SG11202002940QA
(en)
|
2017-11-01 |
2020-04-29 |
Alnylam Pharmaceuticals Inc |
Complement component c3 irna compositions and methods of use thereof
|
TW202023574A
(zh)
|
2018-08-13 |
2020-07-01 |
美商阿尼拉製藥公司 |
B型肝炎病毒(HBV)dsRNA劑組合物及其使用方法
|
JP2022517270A
(ja)
|
2019-01-16 |
2022-03-07 |
ジェンザイム・コーポレーション |
Serpinc1 iRNA組成物およびその使用方法
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
MX2022010413A
(es)
|
2020-02-24 |
2022-09-07 |
Univ Leuven Kath |
Compuestos de pirrolopiridina e imidazopiridina antivirales.
|
WO2021209563A1
(en)
|
2020-04-16 |
2021-10-21 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
AU2021405511A1
(en)
|
2020-12-22 |
2023-06-22 |
Luxembourg Institute Of Health (Lih) |
Conolidine analogues as selective ackr3 modulators for the treatment of cancer and cardiovascular diseases
|
WO2022184898A1
(en)
|
2021-03-04 |
2022-09-09 |
Universiteit Antwerpen |
Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer
|
EP4347541A2
(en)
|
2021-05-31 |
2024-04-10 |
Telix Pharmaceuticals (Innovations) Pty Ltd |
Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof
|
WO2023021132A1
(en)
|
2021-08-18 |
2023-02-23 |
Katholieke Universiteit Leuven |
6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues
|
WO2023046900A1
(en)
|
2021-09-23 |
2023-03-30 |
Katholieke Universiteit Leuven |
Ribonucleoside analogues against -sars-cov-2
|
WO2023241799A1
(en)
|
2022-06-15 |
2023-12-21 |
Université Libre de Bruxelles |
Flavanols for use in the treatment of retroviral infections
|
WO2024062043A1
(en)
|
2022-09-21 |
2024-03-28 |
Universiteit Antwerpen |
Substituted phenothiazines as ferroptosis inhibitors
|